目前和新兴的药物疗法用于治疗胃衰竭
M Ammar Kalas1, Irene Sarosiek1, Richard W McCallum1,2
1Division of Gastroenterology, Department of Internal Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX, USA.
Expert opinion on pharmacotherapy
|April 17, 2024
概括
胃衰竭治疗正在扩大,包括一种新的鼻内甲托克洛普拉米德喷雾剂. 这种配方提供快速吸收,绕过口服药物的局限性,以改善胃患者的症状管理.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 胃衰竭是一种慢性疾病,由于胃排空延迟,会影响生活质量,导致恶心,吐和疼痛.
- 直到最近,FDA批准的有限的药理疗法仍然存在,尽管二十年来治疗选择不断扩大.
研究的目的:
- 审查当前的胃衰竭治疗方法.
- 讨论梅托克洛普拉米德的新型鼻腔配方.
主要方法:
- 审查可用的胃衰竭治疗方式.
- 讨论鼻内甲托克洛普拉米德的药理动力学和益处.
主要成果:
- 鼻内甲基胺通过绕过肝脏的第一通代谢,提供快速吸收 (15分钟内).
- 这种配方克服了口服美托克洛普拉米德的局限性,例如胃肠胃的吸收不良或由于严重症状无法服用口服药物.
结论:
- 最近的进展,包括鼻腔内甲托克洛普拉米德,标志着胃衰竭药理疗法的重大进展.
- 焦点正在转移,不仅仅是改善胃排空,而是解决整体症状缓解以获得更好的临床结果.
相关概念视频
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
312
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
312
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
249
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
249
Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding
123
Enteral nutrition encompasses various methods of delivering nutrition directly to the gastrointestinal (GI) tract, bypassing traditional oral intake. It is particularly beneficial for patients who cannot eat by mouth but have a functioning digestive system. Key methods include nasointestinal feeding, gastrostomy, and jejunostomy, each suited to different clinical scenarios based on the patient's needs and condition.
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
123
Peptic Ulcer Disease IV: Management
91
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
91
Drugs for Treatment of Constipation-Predominant IBS
161
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
161
Glucagon-like Receptor Agonists
319
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
319


